Mepolizumab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2128 publications
Real world efficacy of dupilumab in switchers versus biological naive CRSwNP patients.
Journal: Rhinology
Published: June 23, 2026
In brief: Dupilumab (Dupixent) for allergic fungal rhinosinusitis.
Journal: The Medical letter on drugs and therapeutics
Published: June 15, 2026
Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.
Journal: Human vaccines & immunotherapeutics
Published: June 03, 2026
ICC/WHO-Defined and NGS-Annotated Idiopathic Hypereosinophilia (iHES/iHE): Mutations, Clinical and Treatment Details, and Predictors of Survival.
Journal: American journal of hematology
Published: June 03, 2026
Dupilumab for severe asthma complicated with chronic spontaneous urticaria refractory to omalizumab and mepolizumab: a case report
Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Published: June 03, 2026
Eosinophilic fasciitis: a comprehensive systematic review of clinical, histologic, and therapeutic perspectives.
Journal: Italian journal of dermatology and venereology
Published: May 28, 2026
Mepolizumab improves outcomes in patients with CRSwNP with one or more prior nasal polyp surgeries.
Journal: Rhinology
Published: May 28, 2026
When sleep improves but AHI does not: comments on mepolizumab ± FESS in severe CRSwNP.
Journal: Rhinology
Published: May 21, 2026
Efficacy and safety of mepolizumab in hypereosinophilic syndrome.
Journal: European annals of allergy and clinical immunology
Published: May 21, 2026
Long-term real-world effectiveness of Mepolizumab in EGPA: support for a step-up dosing strategy.
Journal: European annals of allergy and clinical immunology
Published: May 21, 2026
Last Updated: 06/30/2026